Tailored Covalency offers the potential to address a broad spectrum of immune-mediated diseases.
New medicines introduced over the past decade have improved clinical outcomes in certain diseases, but a considerable proportion of patients do not adequately respond to new treatments, some of which are associated with undesirable side effects and long-term consequences, and negatively impact the quality of life.
We believe that the treatment of immune-mediated diseases may ideally benefit from a more tailored approach, where an oral drug could deliver an improved risk benefit by selectively modulating the immune system while reducing off-target activity and/or long-term, irreversible, broad immunosuppression.
Since BTK is present in many immune cells, our focus is to inhibit the dysfunction and root problem of immune mediated diseases. In pemphigus, a part of the skin structure is considered foreign by the immune system and attacked. In immune thrombocytopenia (ITP), platelets and production are mistakenly targeted and destroyed by dysfunctioning immune cells. In IgG4-RD, certain organs are flooded by immune cells leading to swelling, fibrosis and eventual damage. In multiple sclerosis, immune cells target parts of the brain and spinal cord causing inflammation and tissue damage.